PLAY PODCASTS
The IMID Forum

The IMID Forum

431 episodes — Page 1 of 9

Author Interview: Doctor André Lucas Ribeiro, November 2026

Nov 12, 202630 min

ACR 2026: Daily Highlights: Day 4

Nov 11, 20263 min

ACR 2026: Daily Highlights Day 3

Nov 10, 20264 min

ACR 2026 Daily Highlights: Day 2

Nov 9, 20264 min

ACR 2026 Daily Highlights: Day 1

Nov 8, 20263 min

ACR 2026 Preview Podcast

Nov 3, 202620 min

Discussing RA: Comparative safety and remission outcomes of targeted therapies and MTX

Oct 29, 202612 min

Author Interview: Doctor Mark Gibson, October 2026

Oct 27, 202637 min

Discussing PsA: Difficult-to-manage PsA and molecular and clinical responses to zasocitinib

Oct 15, 202617 min

Discussing PsA: Difficult-to-manage PsA and molecular/clinical responses to zasocitinib

Oct 15, 202617 min

Disusisng PsA Sept - Audio only

Oct 15, 202617 min

Discussing RA: Impact of BMI on response to JAK inhibitors in RA

Oct 8, 20267 min

Discussing axSpA: 52-week results from the Phase 3 BE MOBILE trials

Sep 30, 202620 min

Author Interview: Doctor Elise van Mulligen, September 2026

Sep 3, 202621 min

Discussing RA: Biologic effectiveness and treatment persistence in RA

Aug 27, 20268 min

Discussing PsA: Advances in Psoriatic Arthritis Management and Treatment Safety

Aug 20, 202624 min

Author Interview: Professor Axel Finckh and Associate Professor Bente Glintborg, August 2026

Aug 13, 202626 min

Discussing RA: Advanced therapy outcomes in RA

Jul 30, 202627 min

Author Interview: Professor Laura Coates, July 2026

Jul 22, 202626 min

Discussing axSpA: Long-term safety and efficacy of bimekizumab and ixekizumab in r-axSpA

Jul 16, 202623 min

Author Interview: Dr Murat Torgutalp, June 2026

Jul 9, 202629 min

Discussing RA: Infectious complications of RA treatments

Jun 25, 20269 min

Author Interview: Doctor Chung-Mao Kao, May 2026

Jun 23, 202613 min

Discussing PsA: Personalising treatment targets – understanding clinically meaningful improvement

Jun 18, 202613 min

EULAR 2026 Review Podcast

Jun 12, 202639 min

EULAR 2026 Day 4 Highlights Podcast

Jun 6, 20264 min

EULAR 2026 Day 3 Highlights Podcast

Jun 5, 20263 min

EULAR 2026 Day 2 Highlights Podcast

Jun 4, 20265 min

EULAR 2025 Day 1 Highlights Podcast

Jun 3, 20265 min

Discussing RA: Comparative outcomes with upadacitinib in RA

May 28, 20268 min

EULAR 2026 Preview Podcast

May 27, 202622 min

Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis

May 15, 202621 min

Author Interview: Professor Valentino Paci, April 2026

Apr 30, 202640 min

Discussing RA: Updated EULAR recommendations and next-step strategies after TNF inhibitor failure

Apr 30, 202614 min

Discussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile

Apr 14, 202616 min

Author Interview: Professor Helena Marzo-Ortega, March 2026

Apr 9, 202637 min

Discussing RA: Malignancy risk in patients with RA and the evolution of JAKi prescriptions

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper a paper on the malignancy risk in patients with RA initiating b/tsDMARDS, and the evolution of JAKi prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers.

Mar 26, 202610 min

Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeutic switching drivers

Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.

Mar 19, 202633 min

Author Interview: Doctor Carlo Tur, February 2026

Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor Carlo Tur, from the department of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University, Erlangen-Nurnberg., as they discuss his recent paper ‘Effects of different B-cell-depleting strategies on the lymphatic tissue’.

Mar 12, 202629 min

Author Interview - Professor Andrew Cope, 2026

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrew Cope from the Centre for Rheumatic Diseases, King’s College London, London, UK, as they discuss his recent paper ‘Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial’.

Mar 5, 202624 min

Discussing RA: Pain outcomes and drug effectiveness of JAK inhibitors in RA and PsA

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by Taylor et al. where authors report the effects of UPA and ADA on pain in patients with active RA or PsA stratified by inflammatory status, and a paper by Sonomoto et al. which shows the effectiveness of TOF, BAR, UPA and FIL in patients with RA.

Feb 27, 20268 min

Discussing PsA: Risankizumab efficacy across machine learning defined and complex PsA phenotypes

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘classification of patients into distinct PsA phenotypes based on baseline demographics and clinical characteristics using a machine learning approach, and consensus-derived GRAPPA terminology, to support shared clinical decision making, and enable more effective patient stratification in both observational studies and clinical trials.

Feb 13, 202620 min

Author Interview: Professor Matthew Brown, 2026

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Matthew Brown, the Chief Scientific Officer at Genomics England, as they discuss his recent paper ‘Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from Phase 2b/3 trials’.

Feb 3, 202618 min

Discussing RA: Long-term effectiveness and sex differences of JAK inhibitors in rheumatoid arthritis

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by Strand et al. that evaluated TOF efficacy, safety, and persistence by sex, and explored whether age-related factors contribute to differences in treatment response between males and females, and by Alten et al. that explored the long‑term effectiveness of baricitinib and other b/tsDMARDs in patients with RA with early low disease activity or remission.

Jan 29, 20269 min

Discussing RA: UPA outcomes and the impact of GCs on targeted therapies in RA

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he and Doctor Reike Alten will be reviewing two papers. The first paper by Kameda et al. assessed long-term safety and efficacy of UPA over 5 years in Japanese patients with moderate-to- severe active RA and an inadequate response to stable doses of csDMARDs-IR. The second paper by Salvato et al. assessed the impact of chronic oral low-dose GCs on the efficacy and retention rates of JAK inhibitors compared to other mechanisms of action therapies in a cohort of RA patients with inadequate response to TNFi.

Dec 18, 202522 min

Discussing axSpA: Real-world outcomes for patients with axSpA receiving SC infliximab

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered a retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab

Dec 11, 202513 min

Discussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA

Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.

Dec 4, 202520 min

Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.

Nov 27, 20259 min

Author Interview: Professor Filip Rob, 2025

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Filip Rob, the Department of head of the Dermatovenereology at the Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic, as they discuss his recent paper ‘Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients’.

Nov 20, 202525 min

Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2

Webinar highlights! Join Professor Iain McInnes and Drs Grace Wright and Melinda Gooderham as they discuss advancing patient care through an interdisciplinary approach to IMIDs. This webinar provides information on bridging care pathways, advancing IMID treatment, and case studies of interdisciplinary care.

Nov 16, 202517 min